Stockholm3 research suggests a potential reduction of up to 50% in unnecessary biopsies, a 35% decrease in MRI usage, and a 20–30% decrease in low-risk prostate cancer diagnoses, while maintaining the detection rates comparable with the traditional PSA tests for clinically significant prostate cancer [7], [10], [11]. The gene discussed is KLK3; the disease is prostate carcinoma.